Protection of the Kidney with Sodium-glucose Cotransporter 2 Inhibitors: Potential Mechanisms Raised by the Large-scaled Randomized Control Trials

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2018 Nov 28

PMID 30478731

Authors

Satoru Kuriyama

Affiliations

Soon will be listed here.

Abstract

This communication provides a current overview on the renal protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in diabetics. Following the epoch-making publications, the CANVAS Program and the EMPA-REG OUTCOME trial, numerous literature has discussed the mechanisms by which SGLT2 inhibition exerts its cardio-renal protective effects. Some of them reached agreement, while others did not. This review focuses on the hemodynamic aspect and the remaining potential factors relevant to the renal protection which have not been so much taken up by other review papers. Questions unanswered include factors of uric acid, lipids, erythropoiesis and oxidative stress, salt and sympathetic nerve, and the Na-H exchanger in heart and kidney.

References

Carlson S, Roysomutti S, Peng N, Wyss J . The role of the central nervous system in NaCl-sensitive hypertension in spontaneously hypertensive rats. Am J Hypertens. 2001; 14(6 Pt 2):155S-162S. DOI: 10.1016/s0895-7061(01)02083-0. View

Iseki K, Oshiro S, TOZAWA M, Iseki C, Ikemiya Y, Takishita S . Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2002; 24(6):691-7. DOI: 10.1291/hypres.24.691. View

Xiao X, Allen D . The role of endogenous angiotensin II in ischaemia, reperfusion and preconditioning of the isolated rat heart. Pflugers Arch. 2003; 445(6):643-50. DOI: 10.1007/s00424-002-0990-y. View

Mangrum A, Bakris G . Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004; 24(2):168-75. DOI: 10.1016/j.semnephrol.2003.11.001. View

Girardi A, Knauf F, Demuth H, Aronson P . Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol. 2004; 287(5):C1238-45. DOI: 10.1152/ajpcell.00186.2004. View

Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S . Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004; 44(4):642-50. View

Anavekar N, McMurray J, Velazquez E, Solomon S, Kober L, Rouleau J . Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004; 351(13):1285-95. DOI: 10.1056/NEJMoa041365. View

Go A, Chertow G, Fan D, McCulloch C, Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. DOI: 10.1056/NEJMoa041031. View

Nangaku M . Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2005; 17(1):17-25. DOI: 10.1681/ASN.2005070757. View

10.

Rahmoune H, Thompson P, Ward J, Smith C, Hong G, Brown J . Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005; 54(12):3427-34. DOI: 10.2337/diabetes.54.12.3427. View

11.

Haase V . Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol. 2006; 291(2):F271-81. PMC: 4232221. DOI: 10.1152/ajprenal.00071.2006. View

12.

Lago R, Singh P, Nesto R . Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007; 370(9593):1129-36. DOI: 10.1016/S0140-6736(07)61514-1. View

13.

Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-72. DOI: 10.1056/NEJMoa0802987. View

14.

Barretto A, Santos A, Munhoz R, Rondon M, Franco F, Trombetta I . Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol. 2008; 135(3):302-7. DOI: 10.1016/j.ijcard.2008.03.056. View

15.

Caulfield M, Munroe P, ONeill D, Witkowska K, Charchar F, Doblado M . SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008; 5(10):e197. PMC: 2561076. DOI: 10.1371/journal.pmed.0050197. View

16.

Feig D, Kang D, Johnson R . Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17):1811-21. PMC: 2684330. DOI: 10.1056/NEJMra0800885. View

17.

Abdul-Ghani M, DeFronzo R . Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008; 14(6):782-90. DOI: 10.4158/EP.14.6.782. View

18.

Law M, Morris J, Wald N . Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338:b1665. PMC: 2684577. DOI: 10.1136/bmj.b1665. View

19.

Carraro-Lacroix L, Malnic G, Girardi A . Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009; 297(6):F1647-55. DOI: 10.1152/ajprenal.00082.2009. View

20.

Lutken S, Kim S, Jonassen T, Marples D, Knepper M, Kwon T . Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade. Am J Physiol Renal Physiol. 2009; 297(6):F1678-88. PMC: 2801339. DOI: 10.1152/ajprenal.00010.2009. View